Completed PHASE2 INTERVENTIONAL 2-arm NCT00665626

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) (Taski-3)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Sponsor: Rigel Pharmaceuticals

Conditions Rheumatoid Arthritis

Interventions Fostamatinib disodium (R935788) Placebo

Updated 7 times since 2017 Last updated: Mar 29, 2017 Started: May 31, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Rigel Pharmaceuticals and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rigel Pharmaceuticals

Data source: Rigel Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwepen, Belgium , Austin, United States , Aventura, United States , Barranquilla, Colombia , Boca Raton, United States , Bogota, Colombia , Boise, United States , Bordeaux, France , Chicago, United States , Cumberland, United States and 31 more locations